Dutch biotech company MucoVax, Leiden, The Netherlands, recently closed a €3.1 million financing round. This funding will enable the company to accelerate its nutraceutical product development for a range of bioactive milk ingredients with specific functionalities suited for the prevention and treatment of disease.